ReviewFrontiers in pharmacology2025
The aryl hydrocarbon receptor in liver injury: a double-edged sword in roles, mechanisms, and future perspectives.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Aryl hydrocarbon receptor is involved in DNA damage repair after liver injury with diethylnitrosamine in mice.Molecular biomedicine · 2026Article
- CYP1A1 as a conserved metabolic circuit linking environmental sensing to immune regulation.Archives of toxicology · 2026Review
- Aryl hydrocarbon receptor: a multifaceted environmental sensor in liver homeostasis and disease.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aryl hydrocarbon receptor (AhR) is a key regulatory factor that enables the organism to sense and integrate environmental and metabolic signals. Its biological function exhibits a universal "dual nature," a feature that has been relatively well studied in organs such as the skin, lungs, and intestines. However, in the pathological processes of the liver-the central metabolic organ-the specific molecular mechanisms and regulatory networks that determine the functional orientation of AhR (whether protective or detrimental) remain a frontier and highly controversial area of research. This review aims to critically synthesize existing evidence, elucidating how AhR influences the progression of liver injury by regulating apoptosis, stress-induced damage, metabolic homeostasis, autophagy, fibrosis, and tumor development. It further explores the causes of its functional heterogeneity, such as ligand specificity and tissue microenvironment. By analyzing current controversies and cognitive gaps in the field, this article seeks to provide a framework for clarifying the complex role of AhR in liver diseases and to guide future exploration of targeted intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.